and Paxlovid brands. Pfizer also provides medicines and vaccines in various therapeutic areas, such as: Pneumococcal disease, meningococcal disease, tick-borne encephalitis COVID-19 under the ...

Basically, Paxlovid was unsafe for a whole bunch of patients. So for the last couple of years scientists at Pfizer have been doing some nifty chemistry, tweaking the nirmatrelvir molecule in the ...

US biotech Enanta Pharma has filed a lawsuit against Pfizer, claiming that its oral antiviral for COVID-19 Paxlovid infringes one of its patents and seeking damages from the pharma giant.

Pfizer has revealed what it will charge for a five-day course of its oral antiviral Paxlovid for COVID-19 when it starts to see it on the commercial market later this year. The drugmaker has set a ...

However, Pfizer does have challenges ahead. Sales of the company’s Covid-19 products are much less than they were amid the pandemic. Sales of Comirnaty and Paxlovid were about $11 billion in ...

Some on Wall Street now advise selling any rally in U.S. markets. However, these four high-yield dividend stocks are keepers.

British drugmaker GSK told Manhattan prosecutors that a former employee told colleagues Pfizer held back positive results until after the 2020 election. But the former employee, who worked at both ...

Pfizer (NYSE:PFE) is undervalued, trading well below its historical and sector averages despite strong non-COVID revenue growth and cost optimizations. Its expanding pipeline in oncology, obesity ...

Pfizer has disappointed investors for the past three years, but its low valuation could make it attractive now. Its sales may decline a bit in 2025, but management has been targeting long-term ...